Skip to content
Screener

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
Eli Lilly logo
Eli LillyLLY
$588M-0.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.12B
Amgen logo
AmgenAMGN
2.8B0.0%
AbbVie logo
AbbVieABBV
$18M0.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$8K+14.3%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.96B+1,120%
Enterprise value$5.91B+1,289%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 11)
Stockholders’ equity:
Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of March 31, 2026 and December 31, 2025; 137,138 shares issued and outstanding as of March 31, 2026 and December 31, 20252,9312,931
Common stock, $0.001 par value; 545,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 50,167,623 and 48,722,309 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively5049
Additional paid-in capital705,196657,561
Accumulated other comprehensive income (loss)(480)546
Accumulated deficit(220,977)(189,157)
Total stockholders’ equity486,720471,930

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s common stock?
Oruka Therapeutics, Inc. (ORKA) reported common stock of 545M in Q1 2026.
How has Oruka Therapeutics, Inc.'s common stock changed year-over-year?
Oruka Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from 545M to 545M.
What is the long-term trend for Oruka Therapeutics, Inc.'s common stock?
Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s common stock has grown at a 785.7% compound annual growth rate (CAGR), from 10K to 545M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Oruka Therapeutics, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude